The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Buprenorphine vs Methadone Maintenance Treatment for Concurrent Opioid Dependence and Cocaine Abuse
Abstract
BACKGROUND: Buprenorphine, a partial mu-agonist and kappa-antagonist, has been proposed as an alternative to methadone for maintenance treatment of opioid dependence, especially for patients with concurrent cocaine dependence or abuse. This study evaluated whether higher maintenance doses of buprenorphine and methadone are superior to lower doses for reducing illicit opioid use and whether buprenorphine is superior to methadone for reducing cocaine use. METHODS: A total of 116 subjects were randomly assigned to 1 of 4 maintenance treatment groups involving higher or lower daily doses of sublingual buprenorphine (12 or 4 mg) or methadone (65 or 20 mg) in a double-blind, 24-week clinical trial. Outcome measures included retention in treatment and illicit opioid and cocaine use as determined by urine toxicology testing and self-report. RESULTS: There were significant effects of maintenance treatment on rates of illicit opioid use, but no significant differences in treatment retention or the rates of cocaine use. The rates of opioid-positive toxicology tests were lowest for treatment with 65 mg of methadone (45%), followed by 12 mg of buprenorphine (58%), 20 mg of methadone (72%), and 4 mg of buprenorphine (77%), with significant contrasts found between 65 mg of methadone and both lower-dose treatments and between 12 mg of buprenorphine and both lower-dose treatments. CONCLUSIONS: The results support the superiority of higher daily buprenorphine and methadone maintenance doses vs lower doses for reducing illicit opioid use, but the results do not support the superiority of buprenorphine compared with methadone for reducing cocaine use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and Analysis: A Researcher's Handbook
Beaton, A. E., & Keppel, G. (1975) · American Educational Research Journal · doi:10.2307/1162588 · Cited by 5,822
The fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222
Basic and Clinical Biostatistics,
(2002) · Survey of Ophthalmology · doi:10.1016/s0039-6257(02)00360-0 · Cited by 1,809
The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome
Ball, J. C., & Ross, A. O. (1991) · Cited by 903
The Effects of Psychosocial Services in Substance Abuse Treatment
McLellan, A. T. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500150065028 · Cited by 869
Statistical Analysis of Epidemiologic Data
Selvin, S. (2004) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195172805.001.0001 · Cited by 822
Incentives Improve Outcome in Outpatient Behavioral Treatment of Cocaine Dependence
Higgins, S. T. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950070060011 · Cited by 806
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
Gibbons, R. D. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820210073009 · Cited by 719
Cited by
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Linehan, M. M., Dimeff, L. A., Reynolds, S. K., Comtois, K. A., Welch, S. S., Heagerty, P., & Kivlahan, D. R. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00011-x · Cited by 741
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Eap, C. B., Buclin, T., & Baumann, P. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241140-00003 · Cited by 599
Amato, L., Davoli, M., A.Perucci, C., Ferri, M., Faggiano, F., & P. Mattick, R. (2005) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2005.02.007 · Cited by 567
The neurobiology of opioid dependence: implications for treatment
Kosten, T., & George, T. (2002) · Science & Practice Perspectives · doi:10.1151/spp021113 · Cited by 505
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub3 · Cited by 501
Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence
Uchtenhagen, A. (2009) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-17408 · Cited by 490
Opiate versus psychostimulant addiction: the differences do matter
Badiani, A., Belin, D., Epstein, D., Calu, D., & Shaham, Y. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3104 · Cited by 472
Methadone maintenance at different dosages for opioid dependence
Faggiano, F., Vigna-Taglianti, F., Versino, E., & Lemma, P. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002208 · Cited by 406
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402
Renewal of drug seeking by contextual cues after prolonged extinction in rats.
Crombag, H. S., & Shaham, Y. (2002) · Behavioral Neuroscience · doi:10.1037//0735-7044.116.1.169 · Cited by 383
Woody, G. E., Poole, S. A., Subramaniam, G., Dugosh, K., Bogenschutz, M., Abbott, P., Patkar, A., Publicker, M., McCain, K., Potter, J. S., et al. (2008) · JAMA · doi:10.1001/jama.2008.574 · Cited by 361
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R., Kimber, J., Breen, C., & Davoli, M. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub2 · Cited by 360
Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence
Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O'Connor, P. G., & Schottenfeld, R. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055255 · Cited by 351
Self-citationBuprenorphine: A Unique Drug with Complex Pharmacology
Lutfy, K., & Cowan, A. (2004) · Current Neuropharmacology · doi:10.2174/1570159043359477 · Cited by 345
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
Mattick, R. P., Ali, R., White, J. M., O'Brien, S., Wolk, S., & Danz, C. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00335.x · Cited by 285
Martell, B. A., Orson, F. M., Poling, J., Mitchell, E., Rossen, R. D., Gardner, T., & Kosten, T. R. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.128 · Cited by 263
Improving translation of animal models of addiction and relapse by reverse translation
Venniro, M., Banks, M. L., Heilig, M., Epstein, D. H., & Shaham, Y. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0378-z · Cited by 212
Levin, F. R., Mariani, J. J., Specker, S., Mooney, M., Mahony, A., Brooks, D. J., Babb, D., Bai, Y., Eberly, L. E., Nunes, E. V., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.41 · Cited by 179
O’Connor, P., Oliveto, A., Shi, J., Triffleman, E., Carroll, K., Kosten, T., Rounsaville, B., Pakes, J., & Schottenfeld, R. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00194-6 · Cited by 174
Self-citationBentzley, B. S., Han, S. S., Neuner, S., Humphreys, K., Kampman, K. M., & Halpern, C. H. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8049 · Cited by 161
Preston, K. L., Umbricht, A., & Epstein, D. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.4.395 · Cited by 146
Pharmacotherapy for Cocaine Use Disorder—a Systematic Review and Meta-analysis
Chan, B., Kondo, K., Freeman, M., Ayers, C., Montgomery, J., & Kansagara, D. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05074-8 · Cited by 150
Clinical efficacy of buprenorphine: comparisons to methadone and placebo
LING, W. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00059-0 · Cited by 121
Schottenfeld, R. S., Chawarski, M. C., & Mazlan, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60954-x · Cited by 99
Self-citationEffect of methadone maintenance treatment on heroin craving, a literature review
Fareed, A., Vayalapalli, S., Stout, S., Casarella, J., Drexler, K., & Bailey, S. P. (2010) · Journal of Addictive Diseases · doi:10.1080/10550887.2010.531672 · Cited by 95
Neumann, A. M., Blondell, R. D., Jaanimägi, U., Giambrone, A. K., Homish, G. G., Lozano, J. R., Kowalik, U., & Azadfard, M. (2013) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.759872 · Cited by 90
Highfield, D. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00227-5 · Cited by 81
Chan, B., Freeman, M., Ayers, C., Korthuis, P. T., Paynter, R., Kondo, K., & Kansagara, D. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108193 · Cited by 56
Ahmadi, J., Ahmadi, K., & Ohaeri, J. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2003.01218.x · Cited by 58
Coviello, D. M., Cornish, J. W., Lynch, K. G., Boney, T. Y., Clark, C. A., Lee, J. D., Friedmann, P. D., Nunes, E. V., Kinlock, T. W., Gordon, M. S., et al. (2012) · Substance Abuse · doi:10.1080/08897077.2011.609438 · Cited by 58
Heroin anticraving medications: a systematic review
Fareed, A., Vayalapalli, S., Casarella, J., Amar, R., & Drexler, K. (2010) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2010.505991 · Cited by 41
Clinical management of psychostimulant withdrawal: review of the evidence
Li, M. J., & Shoptaw, S. J. (2023) · Addiction · doi:10.1111/add.16093 · Cited by 39
Moderate- vs High-Dose Methadone in the Treatment of Opioid Dependence: A Randomized Trial
Strain, E. C., Bigelow, G. E., Liebson, I. A., & Stitzer, M. L. (1999) · JAMA · doi:10.1001/jama.281.11.1000 · Cited by 6
Metadata
- Authors
- Schottenfeld, R. S.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1997-08-01
- Volume
- 54
- Issue
- 8
- Pages
- 713
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2121153184
- Cited by
- 303
- References
- 67
- FWCI
- 18.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.